NCT05664243: A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 4 planned
- Started
- 8 Sep 2023
- Primary completion
- Dec 2026
- Arms
- 1) Autologous Newly Diagnosed Disease: Phase 2 Arm A
- Results
- None posted
- 23 Dec 2022: Trial registered
- 8 Sep 2023: Trial started